[{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"Cytochrome P450 11A1 | Cytochrome P450 17A1 | Cytochrome P450 11B2 | Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"Cytochrome P450 11A1 | Cytochrome P450 17A1 | Cytochrome P450 11B2 | Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"Cytochrome P450 11A1 | Cytochrome P450 17A1 | Cytochrome P450 11B2 | Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"Cytochrome P450 11A1 | Cytochrome P450 17A1 | Cytochrome P450 11B2 | Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Strongbridge Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dichlorphenamide","moa":"Carbonic anhydrase I | Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.27000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xeris Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Xeris Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Tetris Pharma"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"}]
Find Clinical Drug Pipeline Developments & Deals by Xeris Pharmaceuticals
Filters
Ă—
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
